tTF-NGR + Trabectedin

About Anturec Pharmaceuticals

Anturec Pharmaceuticals is a private, preclinical-to-clinical stage biotech developing a novel vascular-targeted cancer therapy. The company's platform centers on tTF-NGR, a fusion protein designed to selectively occlude tumor blood vessels, leading to tumor death. With its lead program now in a pivotal Phase III trial for soft tissue sarcoma, Anturec is advancing a potentially broad-acting oncology therapeutic. The company is led by its founding scientists and a private investor, with operations split between Frankfurt and Münster, Germany.

Therapeutic Areas